Although involved in the regulation of T cell proliferation and survival (D'Souza et al., 2008), selective BRAF inhibitors have been shown to increase CD8+ lymphocytes in human metastatic melanoma models (Wilmott et al., 2012). This evidence concerns the gene CD8A and metastatic melanoma.